Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Authors
- Jeffrey R. Willis (ORCID: https://orcid.org/0000-0002-6712-1144)
- Kara Gibson (ORCID: https://orcid.org/0009-0001-9016-3481)
- Srinivas R. Sadda (ORCID: https://orcid.org/0000-0002-4939-3306)
- Usha Chakravarthy (ORCID: https://orcid.org/0000-0002-2606-3734)
- Varun Chaudhary (ORCID: https://orcid.org/0000-0002-9988-4146)
- Sascha Fauser
- Stela Vujosevic (ORCID: https://orcid.org/0000-0001-6773-9967)
- Carl Glittenberg (ORCID: https://orcid.org/0000-0002-5562-4529)
- Colin S. Tan (ORCID: https://orcid.org/0000-0003-3088-5690)
- Nancy M. Holekamp (ORCID: https://orcid.org/0000-0001-7850-8515)
- Andreas Maunz (ORCID: https://orcid.org/0000-0002-2784-9456)
- Rishi P. Singh (ORCID: https://orcid.org/0000-0001-5859-8162)
- Ben Lanza
Institutions
- Roche (Switzerland) (CH)
- Queen's University Belfast (GB)
- Cleveland Clinic (US)
- University of California, Los Angeles (US)
- University of Milan (IT)
- Tan Tock Seng Hospital (SG)
- MultiMedica (IT)
- Doheny Eye Institute (US)
- Roche (United Kingdom) (GB)
- Pepose Vision Institute (US)
- Cleveland Eye Clinic (US)
- McMaster University (CA)
Publication Details
- Journal
- Ophthalmology Science
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.xops.2025.100798
- Citations
- 4
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.83
Funders
- Roche
- F. Hoffmann-La Roche
- European Commission